Delian Asparouhov: Anthropic run-rate estimated at $60 billion, Keytruda at $25 billion

Delian Asparouhov: Anthropic run-rate estimated at $60 billion, Keytruda at $25 billion
Anthropic and Keytruda run-rate comparison

Delian Asparouhov draws attention to the notable run-rates of two major entities. Anthropic is estimated to have a run-rate of approximately $60 billion, while Keytruda, a drug that was improved in microgravity, has a run-rate near $25 billion.

Asparouhov highlights that Keytruda's significant run-rate comes from just a single drug, emphasizing the scale of both companies' financial performance.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.